OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) Files An 8-K Other EventsItem 8.01. Other Events.
On June 26, 2017, OWC Pharmaceutical Research Corp. (the "Registrant") filed a Form 8-K announcing that its wholly-owned, Israel-based subsidiary, One World Cannabis Ltd (OWC), had filed a patent application with the United States Patent and Trademark Office (USPTO) for its active cannabinoid-based topical cream. The Form 8-K was accompanied by a press release that, in error, reported that the Patent Application Number was 15/639,2 when, in fact, the correct Patent Application Number is 15/629.230. In all other respects, the Form 8-K filed on June 26, 2017 is correct.
About OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP)
OWC Pharmaceutical Research Corp. is a medical cannabis research and development company. The Company is engaged in the research and development of cannabis-based medical products (the Product Prospects) for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications. The Company also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. As of September 30, 2016, the Company was engaged in two business activities: work with GUMI to commercialize and market the Company’s Electromagnetic Percussion Device (the Device), and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder (PTSD) migraines and a delivery system.